All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Wojciech JurczakAt the 24th Congress of the European Hematology Association (EHA), Wojciech Jurczak from Jagiellonian University, Krakow, PL, discusses first-line therapy in follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Dr. Jurczak draws attention to two studies, that are both changing clinical practice. The first study is GALLIUM for FL, which provided longer progression-free survival (PFS) data. He emphasizes that the more mature the data, the better it is. Dr. Jurczak discusses the first-ever randomized trial in CLL first-line therapy, carried out on 309 patients, where the new BTK inhibitor used provided better PFS and toxicity data.
First-line therapy in FL & CLL
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?